127 related articles for article (PubMed ID: 1330653)
1. The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Constantinou A; Grdina D; Kiguchi K; Huberman E
Exp Cell Res; 1992 Nov; 203(1):100-6. PubMed ID: 1330653
[TBL] [Abstract][Full Text] [Related]
2. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
3. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
Inaba M; Mitsuhashi J; Kawada S; Nakano H
Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400
[TBL] [Abstract][Full Text] [Related]
4. The action of the DNA intercalating agents 4'-(9-acridinylamino) methanesulphon-m-anisidide and 1,4-bis(butylamino) benzo[g]phthalazine in U-937 human promonocytic cells: relationship between cell cycle and differentiation.
Pérez C; Campayo L; Navarro P; García-Bermejo L; Aller P
Biochem Pharmacol; 1994 Jul; 48(1):75-82. PubMed ID: 7519013
[TBL] [Abstract][Full Text] [Related]
5. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
6. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression.
Rius C; Zorrilla AR; Cabañas C; Mata F; Bernabeu C; Aller P
Mol Pharmacol; 1991 Apr; 39(4):442-8. PubMed ID: 1850089
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
9. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
10. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.
Del Bino G; Skierski JS; Darzynkiewicz Z
Exp Cell Res; 1991 Aug; 195(2):485-91. PubMed ID: 1649059
[TBL] [Abstract][Full Text] [Related]
11. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
Woynarowski JM; Sigmund RD; Beerman TA
Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
[TBL] [Abstract][Full Text] [Related]
13. [Effect of etoposide and amsacrine on mitotic progression of GM-130 and Hep-2 cell lines. The flow cytometry assay].
Shatrova AN; Aksenov ND; Poletaev AI; Zenin VV
Tsitologiia; 2003; 45(1):59-68. PubMed ID: 12683237
[TBL] [Abstract][Full Text] [Related]
14. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
15. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
17. Regulation of topoisomerase II expression during the VM-26 induced differentiation of IW32 murine erythroleukemia cells.
Tan SK; Tang SJ; Wang MC; Hwang J; Wang FF
Leuk Res; 1996 Mar; 20(3):249-57. PubMed ID: 8637220
[TBL] [Abstract][Full Text] [Related]
18. Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Hirohashi Y; Hidaka K; Sato S; Kuwano M; Kohno K; Hisatsugu T
Jpn J Cancer Res; 1995 Nov; 86(11):1097-105. PubMed ID: 8567402
[TBL] [Abstract][Full Text] [Related]
19. A new action for topoisomerase inhibitors.
Zucker RM; Elstein KH
Chem Biol Interact; 1991; 79(1):31-40. PubMed ID: 1647887
[TBL] [Abstract][Full Text] [Related]
20. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells.
Roberge M; Th'ng J; Hamaguchi J; Bradbury EM
J Cell Biol; 1990 Nov; 111(5 Pt 1):1753-62. PubMed ID: 2172257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]